InspireMD Q1 revenue $3.4M (+122% YoY); voluntary recall of CGuard Prime 135 cm

InspireMD, Inc.

2026-Q1 EPS reported -$0.16 revenue$3,398,000

Net loss $13.7M ($0.16/share) vs $11.2M loss a year ago; operating expenses rose to $14.7M.
GAAP gross profit $0.7M (20.2% margin); adjusted gross profit $1.2M (34.1%) excluding $0.5M impairment charge.
Voluntary recall of CGuard Prime 135 cm; expected costs $700K returns + $650K inventory/remediation.
FDA approved IDE for CGUARDIANS III trial of SwitchGuard NPS; CGuard Prime 80 cm TCAR approval expected H2 2026.
Original CGuard FDA approval anticipated Q3 2026; over 625 cumulative procedures with CGuard Prime since launch.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.